Katerina Ondraskova^1,2, Matous Cwik³, Ondrej Horky⁴, Jitka Berkovcova⁴, Jitka Holcakova¹, Martin Bartosik¹, Tomas Kazda⁵, Klara Mrazova^1,6, Michal Uher⁷, Igor Kiss³, Roman Hrstka^1,3,*

Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.070116 - 19 January 2026

Abstract Objectives: Cancer treatment relies heavily on accurate diagnosis and effective monitoring of the disease. These processes often involve invasive procedures, such as colonoscopy, to detect malignant tissues, followed by molecular analyses to determine relevant biomarkers. This study aimed to evaluate the clinical performance of droplet digital PCR (ddPCR) for detecting Kirsten Rat Sarcoma Viral Proto-Oncogene (KRAS), Neuroblastoma RAS Viral Oncogene Homolog (NRAS), and B-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) mutations in circulating tumor DNA (ctDNA) from colorectal cancer patients using liquid biopsy. Methods: ctDNA was isolated from colorectal cancer (CRC) patients (n = 110) and analyzed for KRAS, BRAF,… More >

Rabindranath Bera^1,#, Yotaro Ochi^2,3, Ying-Jung Huang¹, Ming-Chung Kuo^1,4, Kenichi Yoshida⁵, Seishi Ogawa², Lee-Yung Shih^1,4,*

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.070259 - 30 December 2025

Abstract Background: Breakpoint Cluster Region-Abelson (BCR::ABL1) fusion protein is essential in the pathogenesis of chronic myeloid leukemia (CML); however, the chronic-to-blast phase transformation remains elusive. We identified novel kinesin light chain 2 (KLC2) mutations in CML-myeloid blast phase patients. We aimed to examine the functional role of KLC2 mutations in leukemogenesis. Methods: To evaluate the biological role of KLC2 mutants (MT) in CML cells, we expressed KLC2-MT in different human CML cell lines harboring BCR::ABL1 and performed immunoblot, immunofluorescence, cell proliferation, differentiation, and apoptosis; Tyrosine kinase inhibitor (TKI)-drug activities; and clonogenic assays for in vitro functional analyses. We co-expressed KLC2-MT… More >

Helen Fenske¹, Ingrid R. Niesman^2,*

BIOCELL, Vol.49, No.12, pp. 2433-2455, 2025, DOI:10.32604/biocell.2025.071078 - 24 December 2025

Abstract Objective: Tyrosinase is the rate-limiting enzyme in the generation of melanin. The feline tyrosinase mutation, G302R, confers temperature-sensitive loss of function, resulting in the familiar Siamese cat phenotype. Crystal or cryoEM structures are elusive for any mammalian tyrosinase to date. Protein misfolding is suggested as a basis for phenotypes resulting from mutant tyrosinases, but this hypothesis needs structural confirmation. Our objective for this study is to confirm misfolding of mutant tyrosinase as a basis for temperature-sensitive phenotypes compared to catalytic dysfunction that may be responsible for other tyrosinase mutant breed phenotypes. Methods: We have employed… More >

KHANH TOAN NGUYEN^*, THI HUONG PHAM, VAN LAM NGO, VAN TUAN BUI, VAN NHAT NGUYEN, THI PHUONG THAO NGUYEN, THI KHANH HA NGUYEN, THI THUY VAN NGUYEN

Oncology Research, Vol.33, No.7, pp. 1667-1677, 2025, DOI:10.32604/or.2025.061905 - 26 June 2025

Abstract Aims: The study aimed to evaluate the effectiveness and adverse events of tyrosine kinase inhibitors (TKIs) in the first-line treatment of advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. Methods: A retrospective study on advanced NSCLC patients with EGFR mutations treated with TKIs as a first-line therapy at Nghe An Oncology Hospital, Vietnam between January 2017 and August 2023. The primary endpoints included objective response rate, progression-free survival, and tolerability. The secondary endpoint was overall survival. Results: A total of 211 patients received first-line treatment with Erlotinib (n = 74), Gefitinib (n… More >

Yinghui Ye^1,#, Yulou Luo^2,#, Yutian Sun³, Yujie Zhang¹, Jiaxin Lin⁴, Ziling Yang⁵, Anping Xu^6,*, Bei Xue^1,*

Oncology Research, Vol.33, No.6, pp. 1383-1404, 2025, DOI:10.32604/or.2025.062584 - 29 May 2025

Abstract Objectives: The tumorigenic progression of Lung adenocarcinoma (LUAD), the predominant NSCLC subtype, is predominantly driven by co-occurring mutations in KRAS proto-oncogene (KRAS)/Tumor protein p53 (TP53). However, their impact on tumor microenvironment (TME) heterogeneity, particularly neutrophil dynamics, remains poorly understood. This present study aims to elucidate how KRAS/TP53 mutations reprogram the TME and develop a neutrophil-centric prognostic signature for LUAD. Methods: Leveraging single-cell RNA sequencing data and transcriptome data, neutrophil subpopulations were identified using Seurat and CellChat R packages, with trajectory analysis via Monocle2 R package. High-dimensional weighted gene co-expression network analysis (hdWGCNA), univariate Cox regression,… More >

ABDUR JAMIL¹, RIMSHA SIDDIQUE², FARYAL ALTAF³, DANIYAL WARRAICH⁴, FAIZAN AHMED⁵, ZAHEER QURESHI^6,*

Oncology Research, Vol.33, No.6, pp. 1289-1300, 2025, DOI:10.32604/or.2025.058790 - 29 May 2025

Abstract Background: Male breast cancer (MBC) is a rare but significant health concern, accounting for less than 1% of all breast cancer cases. Despite its low incidence, it presents unique clinical, genetic, and psychosocial challenges. Genetic predispositions, including BRCA2 mutations and hormonal imbalances, are key factors influencing the development of MBC. However, the rarity of the condition has led to limited research and fewer treatment guidelines specifically for male patients. Methods: A comprehensive literature review was conducted using PubMed, MEDLINE, and Embase databases to identify studies focusing on the epidemiology, risk factors, clinical presentation, diagnosis, treatment,… More >

Gege Liu^#, Houfang Zhang^#, Yunhui Peng^*

BIOCELL, Vol.49, No.4, pp. 519-538, 2025, DOI:10.32604/biocell.2025.061470 - 30 April 2025

Abstract Nucleosomes play a vital role in chromatin organization and gene regulation, acting as key hubs that interact with various chromatin-associated factors through diverse binding mechanisms. Recent research has highlighted the prevalence of mutations in linker histones across different types of cancer, emphasizing their critical involvement in cancer progression. These cancer-associated mutations in linker histones have been shown to disrupt nucleosome stacking and the formation of higher-order chromatin structures, which in turn significantly affect epigenetic regulatory processes. In this review, we provide a comprehensive analysis of how cancer-associated linker histone mutations alter their physicochemical properties, influencing More >

YOUSEF KATIB^1,*, NASSER MULLA²

Oncology Research, Vol.32, No.11, pp. 1803-1809, 2024, DOI:10.32604/or.2024.052358 - 16 October 2024

Abstract Background: Lung cancer (LC) is one of the most common neoplastic diseases and a leading cause of death in Saudi Arabia. Its incidence in Saudi Arabia has increased by more than 3% within two decades. Our study aimed to describe the epidemiological and genetic landscapes of LC in Al-Madinah city in Saudi Arabia. Methods: A retrospective analysis was conducted on the medical records of 65 patients diagnosed with lung cancer between 2015 and 2021 at a single medical oncology center in Al-Madinah city of Saudi Arabia. Results: The mean patients’ age was 59.2 years, with 50… More >

YUZHI LIU^1,#, EVELYNE BISCHOF^2,#, ZHIQIN CHEN¹, JIAHUAN ZHOU³, BEI ZHANG⁴, DING ZHANG⁴, YONG GAO^1,*, MING QUAN^1,*

Oncology Research, Vol.32, No.9, pp. 1429-1438, 2024, DOI:10.32604/or.2024.047309 - 23 August 2024

Abstract Objectives: Human epidermal growth factor receptor 2 (HER2)-targeted therapies have demonstrated potential benefits for metastatic colorectal cancer (mCRC) patients with HER2 amplification, but are not satisfactory in cases of HER2 mutant CRCs. Methods: Consequently, further elucidation of amplifications and somatic mutations in erythroblastic oncogene B-2 (ERBB2) is imperative. Comprehensive genomic profiling was conducted on 2454 Chinese CRC cases to evaluate genomic alterations in 733 cancer-related genes, tumor mutational burden, microsatellite instability, and programmed death ligand 1 (PD-L1) expression. Results: Among 2454 CRC patients, 85 cases (3.46%) exhibited ERBB2 amplification, and 55 cases (2.24%) carried ERBB2 mutation.… More > Graphic Abstract

CHAO TANG^1,#, CHUNYU ZHONG^2,#, JUNHAO ZHU¹, FENG YUAN¹, JIN YANG¹, YONG XU^3,*, CHIYUAN MA^1,3,4,5,*

Oncology Research, Vol.32, No.6, pp. 1079-1091, 2024, DOI:10.32604/or.2024.046007 - 23 May 2024

Abstract Approximately 30%–40% of growth hormone–secreting pituitary adenomas (GHPAs) harbor somatic activating mutations in GNAS (α subunit of stimulatory G protein). Mutations in GNAS are associated with clinical features of smaller and less invasive tumors. However, the role of GNAS mutations in the invasiveness of GHPAs is unclear. GNAS mutations were detected in GHPAs using a standard polymerase chain reaction (PCR) sequencing procedure. The expression of mutation-associated maternally expressed gene 3 (MEG3) was evaluated with RT-qPCR. MEG3 was manipulated in GH3 cells using a lentiviral expression system. Cell invasion ability was measured using a Transwell assay, and epithelial–mesenchymal transition… More >